Effects of sodium/glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary-artery disease and type 2 diabetes mellitus: a retrospective cohort study
AimsPatients with coronary-artery disease (CAD) and type 2 diabetes mellitus (T2DM) are often in a hypercoagulable state and have an increased thrombosis risk. We aimed to evaluate the effects of sodium/glucose cotransporter 2 inhibitors (SGLT2is) on coagulation function and explore their potential...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1588797/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849324226641657856 |
|---|---|
| author | XiaoYue Qin GuoBin Song |
| author_facet | XiaoYue Qin GuoBin Song |
| author_sort | XiaoYue Qin |
| collection | DOAJ |
| description | AimsPatients with coronary-artery disease (CAD) and type 2 diabetes mellitus (T2DM) are often in a hypercoagulable state and have an increased thrombosis risk. We aimed to evaluate the effects of sodium/glucose cotransporter 2 inhibitors (SGLT2is) on coagulation function and explore their potential role in regulating coagulation in these patients.MethodsWe conducted a retrospective cohort study between June 2020 and June 2024 in patients with CAD and T2DM. Eligible patients were assigned to either the SGLT2i or non-SGLT2i group. Clinical information, laboratory tests, and echocardiographic (EKG) examination results were retrieved. We performed inter- and intragroup comparisons of coagulation function measurements before and after treatment, and also conducted regression analysis to assess the impact of treatment on coagulation function.ResultsA total of 121 patients were included, with 49 and 72 in the SGLT2i and non-SGLT2i groups, respectively. After 30 days of treatment, antithrombin III (AT-III) activity increased by 5.39% (P = 0.026) in the SGLT2i group, but slightly decreased in the non-SGLT2i group. SGLT2 is also decreased D-dimer levels by 95 mg/L (group P = 0.051, group:time P = 0.075). Further regression analysis showed a significant interaction between group and time for AT-III and D-dimer (P = 0.026 and P = 0.039). Additionally, prothrombin time (PT) showed a slight increase after SGLT2i treatment.ConclusionSGLT2is could affect coagulation function by prolonging coagulation time and increasing anticoagulatory activity in patients with T2DM and CAD. These drugs could be used to ameliorate hypercoagulable states and reduce thrombosis risk in these patients. |
| format | Article |
| id | doaj-art-b770d043c5fe42108c63fa16aa4c65af |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-b770d043c5fe42108c63fa16aa4c65af2025-08-20T03:48:46ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-05-011210.3389/fcvm.2025.15887971588797Effects of sodium/glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary-artery disease and type 2 diabetes mellitus: a retrospective cohort studyXiaoYue QinGuoBin SongAimsPatients with coronary-artery disease (CAD) and type 2 diabetes mellitus (T2DM) are often in a hypercoagulable state and have an increased thrombosis risk. We aimed to evaluate the effects of sodium/glucose cotransporter 2 inhibitors (SGLT2is) on coagulation function and explore their potential role in regulating coagulation in these patients.MethodsWe conducted a retrospective cohort study between June 2020 and June 2024 in patients with CAD and T2DM. Eligible patients were assigned to either the SGLT2i or non-SGLT2i group. Clinical information, laboratory tests, and echocardiographic (EKG) examination results were retrieved. We performed inter- and intragroup comparisons of coagulation function measurements before and after treatment, and also conducted regression analysis to assess the impact of treatment on coagulation function.ResultsA total of 121 patients were included, with 49 and 72 in the SGLT2i and non-SGLT2i groups, respectively. After 30 days of treatment, antithrombin III (AT-III) activity increased by 5.39% (P = 0.026) in the SGLT2i group, but slightly decreased in the non-SGLT2i group. SGLT2 is also decreased D-dimer levels by 95 mg/L (group P = 0.051, group:time P = 0.075). Further regression analysis showed a significant interaction between group and time for AT-III and D-dimer (P = 0.026 and P = 0.039). Additionally, prothrombin time (PT) showed a slight increase after SGLT2i treatment.ConclusionSGLT2is could affect coagulation function by prolonging coagulation time and increasing anticoagulatory activity in patients with T2DM and CAD. These drugs could be used to ameliorate hypercoagulable states and reduce thrombosis risk in these patients.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1588797/fullsodium/glucose cotransporter 2 inhibitorscoronary-artery diseasetype 2 diabetes mellituscoagulation profileactivated partial thromboplastin time |
| spellingShingle | XiaoYue Qin GuoBin Song Effects of sodium/glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary-artery disease and type 2 diabetes mellitus: a retrospective cohort study Frontiers in Cardiovascular Medicine sodium/glucose cotransporter 2 inhibitors coronary-artery disease type 2 diabetes mellitus coagulation profile activated partial thromboplastin time |
| title | Effects of sodium/glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary-artery disease and type 2 diabetes mellitus: a retrospective cohort study |
| title_full | Effects of sodium/glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary-artery disease and type 2 diabetes mellitus: a retrospective cohort study |
| title_fullStr | Effects of sodium/glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary-artery disease and type 2 diabetes mellitus: a retrospective cohort study |
| title_full_unstemmed | Effects of sodium/glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary-artery disease and type 2 diabetes mellitus: a retrospective cohort study |
| title_short | Effects of sodium/glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary-artery disease and type 2 diabetes mellitus: a retrospective cohort study |
| title_sort | effects of sodium glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary artery disease and type 2 diabetes mellitus a retrospective cohort study |
| topic | sodium/glucose cotransporter 2 inhibitors coronary-artery disease type 2 diabetes mellitus coagulation profile activated partial thromboplastin time |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1588797/full |
| work_keys_str_mv | AT xiaoyueqin effectsofsodiumglucosecotransporter2inhibitorsonthecoagulationprofileinpatientswithcoronaryarterydiseaseandtype2diabetesmellitusaretrospectivecohortstudy AT guobinsong effectsofsodiumglucosecotransporter2inhibitorsonthecoagulationprofileinpatientswithcoronaryarterydiseaseandtype2diabetesmellitusaretrospectivecohortstudy |